Maura Calvani1
Annalisa Dabraio1,2Angela Subbiani1,2
Daniela Buonvicino2Veronica De Gregorio1,2Sara Ciullini Mannurita1Alessandro Pini3
Patrizia Nardini3
Claudio Favre1
Luca Filippi4*- 1Department of Paediatric Haematology-Oncology, A. Meyer University Children’s Hospital, Florence, Italy
- 2Department of Health Sciences, University of Florence, Florence, Italy
- 3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 4Neonatal Intensive Care Unit, Medical Surgical Feto-Neonatal Department, A. Meyer University Children’s Hospital, Florence, Italy
Understanding the mechanisms of immune tolerance is currently one of the most important challenges of scientific research. Pregnancy affects the immune system balance, leading the host to tolerate embryo alloantigens. Previous reports demonstrated that β-adrenergic receptor (β-AR) signaling promotes immune tolerance by modulation of NK and Treg, mainly through the activation of β2-ARs, but recently we have demonstrated that also β3-ARs induce an immune-tolerant phenotype in mice bearing melanoma. In this report, we demonstrate that β3-ARs support host immune tolerance in the maternal microenvironment by modulating the same immune cells populations as recently demonstrated in cancer. Considering that β3-ARs are modulated by oxygen levels, we hypothesize that hypoxia, through the upregulation of β3-AR, promotes the biological shift toward a tolerant immunophenotype and that this is the same trick that embryo and cancer use to create an aura of immune-tolerance in a competent immune environment. This study confirms the analogies between fetal development and tumor progression and suggests that the expression of β3-ARs represents one of the strategies to induce fetal and tumor immune tolerance.
Introduction
Starting From Immune Tolerance
Immunological privileges such as immune tolerance represent the most powerful mechanism that preserves life. Understanding the mechanism of immune tolerance can lead to new strategic therapies in several contexts, as in minimizing the use of toxic drugs in transplants and in establishing more effective immune responses and vaccines for cancers and infection.
Cancer and embryo share similar mechanisms to sustain their progression: both (i) grow in a hypoxic and catecholamine-rich environment and (ii) tolerate a “foreign body” by creating an immune-tolerant microenvironment.
Immune Tolerance in Fetus and Cancer
The maternal immune tolerance is one of the most intriguing and powerful mechanisms in current biology. During pregnancy, the maternal immune system actively tolerates embryo alloantigens, leading to fetus development (1). At the beginning of pregnancy, after conception, the endometrium converts into decidua to promote embryo implantation and the interface between fetus and maternal tissues becomes an immunologically privileged site (2). Several immune cells in the subpopulation recruited at the fetal–maternal interface are involved in maternal immune tolerance.
Recent data show that successful pregnancy requires not only fetal but also placental immune tolerance, contributing to the promotion of an immune-tolerant environment for the fetus. The human fetus is continuously exposed to self-antigens, maternal alloantigens, and nutritional antigens transferred across the placenta that its immune system must learn to tolerate. Moreover, the human placenta, although not an immune organ by definition, is highly active in promoting an immune-tolerant environment. Several different immune subpopulations are currently under investigation for the study of immune tolerance in both pregnant women and cancer patients. Actually, cancer is a foreign body for the host and thus different immune subpopulations are needed to sustain an immune-tolerant microenvironment. Here, we proposed a similarity between placenta and tumor microenvironment (TME) in promoting immune tolerance.
Among the different subpopulations involved in fetal and cancer immune tolerance, myeloid-derived suppressor cells (MDSCs) are activated at the fetal–maternal interface by interaction with trophoblast cells, and suppress T cell activation promoting Foxp3 expansion. In cancer, MDSCs induced the upregulation of IL-10 that downregulates macrophage IL-6 and IL-12 and tumor necrosis factor (TNFα) production, thereby polarizing tumor-associated macrophages (TAMs) toward a tumor-promoting M2 phenotype (3–5). Furthermore, cancer MDSCs block natural killer (NK) activity and their INF-γ secretion leads to anergic NK (6). Recent studies have shown that MDSCs and TAMs can promote angiogenesis by the induction of matrix metallopeptidase 9 (MMP9), vascular endothelial growth factor (VEGF), and IL-1β (7–13).
Regulatory T cells (Treg) are the predominant cells in both pregnancy and cancer and confer immunologic protection to embryo and cancer. Immune-suppressive maternal Foxp3+ Treg cells, detected at the fetal–maternal interface are critical to create and maintain a fetal–maternal-tolerant microenvironment by blocking alloreactive Th1 cells (14, 15). An altered Th1/Th2 cytokine balance with Th2 predominance and T-cell transient anergy makes the placental microenvironment an immunologically privileged site (16). Moreover, Treg cells participate in indoleamine-2,3-dioxygenase (IDO) (17) and placental heme oxygenase (HO)-inducible isoform expression, engaged in Foxp3-mediated immune suppression (18).
Recently, it has been reported that Treg cells accumulated in the human and murine decidua constitutively express cytotoxic T-lymphocyte antigen 4 (CTLA-4) (19, 20) and inhibit the interactions between CD28 expressed on T cells and their ligands, B7-1 and B7-2, expressed on antigen-presenting cells, such as macrophages or dendritic cells. Blockade of this interaction has been shown to induce antigen-specific peripheral tolerance (21–23). Fetal-specific Treg cells persist also after delivery, maintain tolerance to preexisting fetal antigens, and rapidly re-accumulate during subsequent pregnancy. Therefore, pregnancy imprints a sort of regulatory memory through the specific maternal Treg cells (24). Interestingly, a high number of maternal cells cross the placenta and, in fetal lymphoid tissues, induce the development of Treg cells (25).
In the human fetus, Treg cells are precociously detected, as early as 13 weeks of gestation (26). Their prevalence is significantly higher in fetal lymphoid tissues (on average, 15–20% of CD4+ T cells) than that observed in adult lymph nodes (usually less than 5%), and these cells are able to suppress the proliferation and function of both CD4+ and CD8+ T cells (27). Moreover, Treg cells induce immune suppression through the production of inhibitory cytokines, such as Transforming Growth Factor beta (TGF-β), IL-10, and IL-35 (28, 29), depleting the availability of IL-2, or killing the effector or Antigen-Presenting Cells (APC), thanks to the upregulation of perforin, production of granzyme B, or interaction with Fas/FasL (Fas Ligand) (30).
Furthermore, Treg cells are activated by the ICOS (inducible T−cell co-stimulator)−ICOSL (ICOS ligand) and programmed cell death-1 (PD−1)/PD-ligand 1 (PD-L1) pathways in conjunction with the inhibition of effector T cells by the lymphocyte activation gene−3 (LAG−3)−MHC class II pathway (31). The interaction between CTLA−4 expressed by Treg cells and CD80/86 on APCs promotes IDO secretion (32). It is well known that the expression of IDO and tryptophan 2,3-dioxygenase (TDO) leads to tryptophan depletion in the TME and causes T cell dysfunction (33).
Natural killer cells represent the majority of immune cells present in the fetal–maternal interface of the pregnant uterus, where they show a specific function and a peculiar phenotype during pregnancy (34). While circulating conventional natural killer (cNK) cells are cytotoxic lymphoid cells programmed to have an active role in promoting leukocyte activation and immune surveillance against infections and cancer (35), distinct subsets of resident NK cells have been described in specific tissues, such as the uterus (36). In contrast to cNK cells, NK cells detected in the decidua during pregnancy, referred to as decidual NK (dNK), appear to be primarily responsible for promoting placentation (37), as suggested by the expression of specific inhibitory receptors (KIR) and poor cytotoxic activity (38).
Decidual NK show a distinct phenotype compared to peripheral blood. In fact, despite that dNK have abundant intracellular granules containing granzymes, granulysin, and perforin, they are poorly cytotoxic, probably as a consequence of the recognition of human leukocyte antigens-alpha chain E (HLA-E) expressed on trophoblasts (39), even though dNK cell cytotoxicity can increase in an inflammatory environment (40). dNK appear to be involved in the promotion of immune tolerance, thanks to the interaction with decidual myelomonocytic CD14(+) cells which induce Treg cell expansion, through the expression of IDO, the production of TGF-β, or an interaction mediated by CTLA-4 (41).
Moreover, NK infiltration represents instead a positive prognostic marker in cancer cells, due to their cytotoxic activity (42–44), but unfortunately, frequently the number of infiltrated NK is reduced, and their activity is not sufficient to counteract tumor progression (45, 46).
β-Adrenergic System and Immune Regulation
Stress, catecholamine synthesis, and β-adrenergic receptors (β-ARs) have long been investigated as regulators of many physiological processes, including cardiac and pulmonary physiology and immune responses. The effects of catecholamine epinephrine and norepinephrine are mediated by β-ARs which belong to the G-protein-coupled receptors family and classified into three subtypes widely expressed in various tissues: β 1-, β2-, and β3-AR. It is well known that β-AR signaling is involved in the regulation of several cellular processes that contribute to cancer initiation and progression (47–50): in particular, downregulation of antitumor responses and accumulation of immunosuppressive cells, including TAMs and MDSCs, is induced by stressful conditions. Several in vitro and in vivo studies have demonstrated the behavioral stress and catecholamine involvement in promoting cancer progression through decreased NK activity and immune suppressive effects (51–57). Norepinephrine, the β-AR agonist isoproterenol, and the β2-AR selective-agonist metaproterenol inhibit NK cell cytotoxic activity in splenocytes, by downregulating perforin, granzyme B, and IFN-γ at the mRNA and protein levels (58). Similarly, stress due to immobilization in rats induces an upregulation of catecholamines and, consequently, a reduction in NK cytotoxicity (59). Moreover, Shakhar G. et al. have shown that β-AR agonism remarkably suppresses NK activity and this compromises host resistance to mammary adenocarcinoma MADB106, an NK-sensitive tumor, in rats (60). The same result is observed in CRNK-16 leukemia where stress leads to suppression of NK activity sufficient to promote tumor development (61). In human patients, apparent conflicting results of clinical studies have been reported: elevated NK activity was reported after epinephrine infusion (62), open-heart surgery (63), or physical exercise (64). However, subsequent studies suggested that this increase was attributable to a marked, but transitory, increase in the number of circulating NK cells, rather than to an increase in activity per NK cells (65). The increase in circulating number of NK cells occurs during the time of elevated catecholamine levels and dissipates shortly after their decline (66).
Recently, β2-AR has been detected on Treg cells. β2-AR signaling, following norepinephrine stimulation, improves the suppressive properties of Treg cells, associated with a decrease in IL-2 expression, and increases the expression of CTLA-4, a molecule that promotes T-cell anergy, improving Treg cell suppressive function in a PKA-dependent manner. In addition, β2-AR signaling stimulates Treg-cell-mediated conversion of CD4+ Foxp3– cells (memory T-cells) into Foxp3+ iTreg (induced Treg) cells, in a PKA-dependent manner, improving Treg cells’ suppressive function (67). Moreover, MDSCs have been reported to be increased in mice exposed to chronic stress (68) and in patients who reported high levels of stress, suggesting that they may be a contributing factor to the immune suppression as observed in breast cancer patients (69). Experimental studies demonstrated that in vitro treatment with norepinephrine significantly enhanced the expansion of the MDSC population, resulting in suppression of T-cell proliferation, suggesting a role of catecholamines in myeloid cell differentiation and function (70).
In summary, the current literature suggests that β-adrenergic activation promotes immunosuppression, as indirectly confirmed by the increased survival rate and the improved response to immunotherapy in melanoma patients (71). However, so far, the focus has been almost exclusively on β2-AR. Recently, a great interest has accrued regarding the role played by the β3-AR in the promotion of fetal and cancer growth and in the induction of an immune-tolerant environment.
β-Adrenergic System and Fetal and Cancer Development
The role of β-adrenergic signaling in pregnancy and the cancer microenvironment is widely reported (47, 72, 73).
Catecholamines are required for mouse fetal development and postnatal survival, as demonstrated by lethality at mid-gestation after blocking their biosynthetic pathway (74, 75). Moreover, during fetal development, catecholamines modulate fetal circulation in hypoxic conditions by reducing the fetal heart rate (72, 73) and preserve heart and brain glucose homeostasis, and their increase at birth is essential to neonatal adaptation, for example to facilitate delivery and induce surfactant production (72, 73, 76).
Several studies show that catecholamines released during stress and β-AR signaling are able to regulate multiple cellular processes that accelerate tumor progression, including cancer cell growth, migration, and angiogenesis, leading to reduction in patient overall survival (47, 51). Among β-ARs, β2-AR is considered the principal receptor subtype involved in the modulation of catecholamine effect in cancer (77), and it may explain why non-selective β-AR blockers (acting on β1- and β2-AR) provide protection against different types of cancer (78–80).
β3-Adrenergic Receptor in Fetal and Cancer Development
The roles played by β3-AR in embryonic development and fetal life remain poorly understood. However, studies report β3-AR expression in human and animal germ cells, where it induces motility (81), in pre-implantation embryos (82, 83), during the first stages of embryogenesis (84), in embryo tissues, and in placenta (85, 86). Moreover, β3-AR is upregulated in the human pregnant myometrium where inhibits spontaneous contractions and represents the predominant subtype over β2-AR (87, 88). These data suggest a role of β3-ARs in the promotion of fecundation, embryo implantation, and growth.
Recently, a growing number of studies have demonstrated the emerging role of β3-AR signaling in cancer development and progression. β3-AR expression has been reported in different tumors, including colon cancer (89), leukemia cells (90), and human vascular tumors (91). In addition, the Trp64Arg polymorphism in ADRB3 (β3-AR gene) was reported to be associated with susceptibility to endometrial cancer and decreased risk for breast cancer, especially when associated to Gln27Glu polymorphism in ADRB2 (β2-AR gene) (92, 93). A recent study in β1-, β2-AR, and β1/β2-AR knockout mice has suggested that not only β2- but also β3-AR result to be actively involved in prostate cancer development (94). Moreover, in melanoma B16F10 cells, we have demonstrated that β3-AR is expressed and significantly upregulated after the exposure to hypoxia, promoting VEGF production in a nitric oxide (NO)-mediated manner. In mice bearing melanoma, we have recently reported that β3-AR blockade reduces tumor volume and the development of tumor vasculature, through decreased cell proliferation and increased apoptosis of melanoma cells (95–97). Recently, the correlation between β3-AR expression and melanoma aggressiveness has been demonstrated in human melanoma tissue samples. This study, for the first time, detected β-AR expression not only on the surface of cancer cells but also in stromal, inflammatory, and vascular cells of TME, where β3-AR was able to enhance melanoma cells, to respond to environmental stimuli, to increase cancer cell motility, and to induce stem-like traits. Finally, β3-AR stimulation in melanoma accessory cells promotes stromal reactivity by inducing pro-inflammatory cytokine production and vasculogenesis, sustaining melanoma growth and aggressiveness, through the ability of pro-inflammatory cytokines to recruit circulating stromal cell precursors (98).
Hypothesis
Is β3-Adrenergic Receptor Functional for Cancer and Fetus Immune Tolerance?
β3-ARs located in the endothelium of human coronary arteries, for example, are 2- to 3-fold more expressed in failing compared with non-failing canine (99) and human hearts (100) and induce an adrenergic-induced vasodilatation through the NO pathway (101). These data suggest that β3-AR upregulation may represent a compensatory mechanism, induced by hypoxia, able to preserve myocardial perfusion during ischemia (101). Similarly, β3-ARs are upregulated in different hypoxic β1 scenarios, such as the mouse model of oxygen-induced retinopathy, the most widely used animal model of retinopathy of prematurity, during the hypoxic phase (102, 103). Also, in this case the demonstration that β3-ARs modulate VEGF release in response to hypoxia through the NO pathway confirms the compensatory mechanism of these receptors, useful to correct retinal hypoxia (104). In conclusion, hypoxia appears to be the ideal environment to induce β3-AR expression, and this is a further similarity between embryo and cancer, where β3-ARs are significantly upregulated under hypoxia conditions (91–98, 105).
Since the involvement of β-ARs in both embryo and cancer development, the similarities between fetal and cancer immune tolerance and, finally, the role, recently demonstrated, of β3-ARs in the promotion of cancer immune escape, we supposed that β3-ARs played a pivotal role also in the regulation of fetal tolerance.
Our recent study, performed in a mouse model of melanoma, has investigated the potential role of β3-ARs in immune-tolerance regulation, evaluating the effect of β-AR blockade on the number and activity of immune cell subpopulations (Treg, NK, CD8, MDSC, macrophages, and neutrophils). First, we described that both β2- and β3-ARs were expressed in mouse peripheral blood mononuclear cells, but only β3-ARs showed a reversible upregulation under hypoxic conditions, followed by a fast downregulation after oxygen re-exposure. Interestingly, β3-ARs were significantly upregulated in NK, Treg, and MDSC infiltrating the tumor if compared with circulating cells. In this study, antagonism of both genetic and pharmacologic β3-ARs reduced melanoma growth in vivo, and this effect was concomitant with a significant increase in NK and CD8 number and cytotoxicity and a strong reduction in Treg and MDSC within the tumor mass (105). Treatment with β3-AR antagonists modified the environment rich in M2 macrophages and N2 neutrophils, enhancers of immune escape in an immune-competent M1 and M2 TME. This study did not evaluate specifically the cause–effect relationships between tumor cell death and immune modulation. However, the observation that pretreatment of PBMC under hypoxia with a selective β3-AR antagonist induced an increase in tumor cell death suggests a direct effect of β3-AR present in the immune cell subpopulation (105).
We hypothesize that hypoxia, through the upregulation of β3-AR, promotes the biological shift toward a tolerant immunophenotype and that this is the same trick that embryo and cancer use to create an aura of immune tolerance in a competent immune environment.
Materials and Methods
In vivo Experiment on Pregnant Mice
In vivo experiments were carried out according to the European Union (EU) guidelines for animal care procedures and the Italian legislation (DLgs 26/2014) application of the EU Directive 2010/63/EU. The pregnancy model was established using C57BL/6 mice, co-caging fertile male with adult females overnight. The following morning after the vaginal plug, detection was designated as day 0.5 of pregnancy. Pregnant mice were subcutaneously treated twice a day with SR59230A, CAS: 174689-39-5 (10 mg/kg, Sigma-Aldrich, Saint Louis, MO, United States), or with a physiological solution (vehicle) starting from day 12.5 to day 17.5 of pregnancy. At day 17.5 of pregnancy, 8 dams were sacrificed and the placentas and the maternal deciduae were collected. Briefly, the implantation sites were dissected from the uterus; each placenta/decidua was separated from both the uterine wall and the chorioallantoic membrane and the decidua was gently detached from the placental surface. Eight dams were immediately euthanized after the delivery, and the placentas were rapidly collected and washed with a physiological solution. Placentas were digested in an RPMI 1640 medium containing collagenase D and DNase I for 30 min at 37°C. The total suspension was filtrated through a 70-μm-mesh strainer and centrifuged in conical polypropylene tubes containing Ficoll–Hystopaque. The gradient of mononuclear cells was washed and used for cytofluorimetric analysis.
Real-Time and Hypoxic Stimulation
For the evaluation of β3-AR expression under normoxic and hypoxic conditions, PBMC were isolated from mouse placental blood with Ficoll–Hystopaque gradient. Then, cells were incubated for 24 h under standard conditions (at 37°C in a humidified incubator with 5% CO2) at 21% O2 for normoxia or 1% O2 hypoxia. After 24 h, cells were lysed and cDNA was obtained from 500 ng of total RNA using iScript gDNA Clear cDNA Synthesis Kit (Bio-Rad, United States). The expression levels of the Adrb3 gene were analyzed through quantitative real-time PCR (qRT-PCR) with the use of SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, United States) according to the manufacturer’s instruction and the specific primers (Bio-Rad Assay ID: qMmuCED0001037) in a CFX96 Touch System instrument (Bio-Rad, United States). The normalization was performed using Tbp and Hprt as housekeeping genes (Bio-Rad Assay ID: qMmuCID0040542 and qMmuCID0005679), and the analysis was done using the ΔΔCt method.
Flow Cytometry
For the evaluation of β3-AR expression on MDSC, NK, and Treg, cells were isolated from mouse placenta and 50 μl of resuspended cells was marked with β3-AR antibody Ab94506. After 15 min of incubation, cells were washed and resuspended in PBS buffer and marked with 1 μl of FITC-conjugated secondary antibody. Then, cells were washed and resuspended in 200 μl of PBS for FACS analysis.
For MDSC, NK, and Treg marker expression, cells isolated from mouse placenta were incubated and stained with appropriate dilutions of various combinations of the following fluorochrome-conjugated antibodies: anti-CD45-VioBlue or VioGreen (130-110-664, 130-110-665), anti-NKp46-FITC (130-102-300), anti-CD8a-VioBlue (130-102-431), anti-CD3e (17A2)-PE Vio 770 (130-109-839), anti-CD107a-PE (130-102-219), anti-CD161 (NK1.1)-PercCP Vio700 (130-103-963), anti-CD25-PE (130-102-593), anti-CD4-PerCP Vio700 (130-123-213), anti-CD127-APC (130-102-529), anti-CD11b-APC Vio770 (130-109-288), anti-Gr1-PE (130-102-426), anti-CD106-PE (130-116-323), and anti-CD49b-PE (130-108-174). All antibodies were obtained from Miltenyi Biotec, Gladbach, Germany.
Gating strategies for cell detection are reported in Supplementary Figure S1.
Cell Viability
To distinguish dead from living cells, Viobility 405/520 (120-028-574), and 488/520 (120-028-575) Fixable Dyes obtained from Miltenyi Biotec and analyzed by flow cytometry were used.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software by one-way and two-way analysis of variance (ANOVA), followed by the post hoc Bonferroni’s test for comparisons of multiple groups. Values are presented as mean ± SEM, n = 4 per group. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ****P < 0.0001, and SR59230a-treated mice compared with vehicles.
Results
Since β3-AR and catecholamine are involved in immune tolerance, we evaluated the expression of this receptor in placental tissues compared with blood samples of healthy mice. Data shown in Figure 1 reveals an increased expression of β3-AR in MDSC, NK, and Treg populations of placenta tissues compared to blood samples.
Figure 1. Placental tissues show β3-AR expression increased respect to placental blood samples. FACS quantification of β3-AR expression in NK, Treg, and MDSC. NK (NKp46+/NK1.1 + gated on CD3-/CD45+/β3-AR+), Treg (CD25+/CD127–/β3-AR + gated on CD45+/CD4+) and MDSC (CD11b+, GR1 + β3-AR + gated on CD45+) of placental tissues compared with blood samples of healthy mice. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, placental tissues compared with placenta blood samples.
To identify whether β3-ARs regulate immune tolerance also in vivo, female mice at the second week of pregnancy received β3-AR-antagonist SR59230a. Treatment was started on day 12 and continued for 5 days. The animals were sacrificed on day 17. β3-AR blockade increased NK number and cytotoxicity (evaluated by expression of CD107a) and attenuated MDSC and Treg number in mouse placentas (Figure 2). In vivo data confirm that β3-ARs support host immune tolerance in the maternal microenvironment by modulating different immune cell populations.
Figure 2. β3-AR antagonism in vivo reverts immune-tolerant phenotype in placenta. Analysis of immunologic phenotype in pregnant mouse placenta (n = 4) at day 17 of pregnancy. FACS quantification of NK (NKp46+/NK1.1 + gated on CD3-/CD45+), Treg (CD25+/CD127– gated on CD45+/CD4+), and MDSC (CD11b+, GR1 + gated on CD45+) in pregnant mice treated with SR59230a. *P < 0.05, **P < 0.01, and ****P < 0.0001, treated mice compared with vehicle mice.
In vivo β3-AR blockade had a different effect on decidual cells (Figure 3). There is no significant variation in NK expression. Instead, the deciduous NK and dNK (evaluated by the expression of CD49b) show an opposite trend: their expression is increased with the β3-AR blockade. This response agrees with the different phenotype of the dNK reported in literature. It was not possible to evaluate any changes in decidual MDSC expression because this population was not found. As regards the other populations, the data showed an increase in CD8 and a decrease in Treg cells. The increase in CD8 shows an involvement of T cell toxicity.
Figure 3. β3-AR antagonism in vivo reverts immune-tolerant phenotype in decidua. Analysis of immunologic phenotype in pregnant mouse decidua (n = 4) at 2 weeks of pregnancy. FACS quantification of NK (NKp46+/NK1.1 + gated on CD3-/CD45+, CD49b), Treg (CD25+/CD127– gated on CD45+/CD4+) in pregnant mice treated with SR59230a. *P < 0.05, **P < 0.01, and ***P < 0.001, treated mice compared with vehicle mice.
To clarify a possible role on the effect of hypoxia on β3-ARs, we evaluated the expression of the ADRB3 gene in mice PBMC through PCR real time. Data reported in Figure 4A show an increase in ADRB3.
Figure 4. Hypoxia induces an increased expression of ADRB3 and β3-AR antagonism in vivo promotes a different immune-tolerant phenotype in placenta after birth. (A) ABRB3 gene expression analyzed by quantitative real-time PCR in mice PBMC isolated from placental blood and incubated for 24 h under normoxic (21% O2) and hypoxic (1% O2) conditions. (B) Analysis of immunologic phenotype in pregnant mouse placenta (n = 4) after birth. FACS quantification of NK (NKp46+/NK1.1 + gated on CD3-/CD45+), Treg (CD25 + gated on CD45+/CD4+), and MDSC (CD11b+, GR1 + gated on CD45+) in pregnant mice treated with SR59230a. ***P < 0.001, treated mice compared with vehicle mice.
To demonstrate the crucial role of hypoxia, we decided to repeat the experiment on mouse placentas immediately after birth, to indirectly demonstrate the hypoxic role. Indeed, after birth the effects of hypoxia in the last stages of pregnancy are no longer found. As results showed, SR59230A did not change the immune population compared with the analysis made in placenta at 17 day (Figure 4B).
In conclusion, this explorative study suggests that this receptor, usually expressed in hypoxic environments, participates in the local origin of fetal immune tolerance (Figure 5). Further studies need to be conducted for understanding the real role of β3-ARs.
Figure 5. Supposed β3-AR blockade involvement in immune tolerance process. Schematic representation of embryo and cancer immune-tolerance regulation by β3-ARs.
Discussion
Recently, β3-ARs have been demonstrated to be involved in cancer-related immune tolerance under hypoxic conditions (105). It is well known that hypoxia plays a crucial role in fetus development and in cancer progression, participating in processes such as angiogenesis, apoptosis, cell migration, invasion, and metastasis (106, 107). Actually, early human placental tissue develops in a physiologically hypoxic environment, such as required to induce specific placental metabolic activities (108). Moreover, β3-ARs are upregulated and represent the predominant subtype over β2-ARs in the human pregnant myometrium (87), where they inhibit spontaneous contractions (88). Here we postulate that the relationship linking hypoxic upregulation of β3-ARs and promotion of immune tolerance recently demonstrated to enhance cancer progression (105) actually follows the same mechanisms originally foreseen to guarantee fetal tolerance.
Since β3-ARs is involved in various hypoxic scenarios in pathological and physiological states, including pregnancy, in this work we have shown that β3-ARs is strongly induced in the immune subpopulations responsible for immune tolerance and that occurs because the intrauterine environment is hypoxic.
In this respect, we have recently demonstrated that β3-ARs are actively involved in all the different scenarios where hypoxia induces important steps necessary to ensure progression of cancer and/or embryo.
β3-ARs, in fact, participate in the promotion of angiogenesis (necessary for tumor progression but also for placenta development), through an axis NO-VEGF mediated (95–98, 105).
Recently, our studies showed that β3-ARs are actively involved in the stimulation of a metabolic shift (necessary in the development of a metabolism specifically programmed to live in a hypoxic environment) through the promotion of aerobic glycolysis (109), yet another common feature shared by early preimplantation mammalian embryo (110), decidua during early pregnancy (111), and tumors (112, 113). Both cancer cells and embryos increase the uptake of glucose and the expression of glycolytic enzymes to obtain energy for growth (Warburg effect). This metabolic shift favors their proliferative activity since this metabolic pathway produces a large number of useful intermediates to secondary biosynthetic pathways and induces an increased export of lactate, useful to facilitate the trophoblast or tumor infiltration (114). It has been reported that both in cancer and embryonic stem cells, β3-ARs promote this metabolic shift, not only inducing the specific glycolytic cytoplasmic enzymes but also promoting the expression of UCP-2 (uncoupling protein-2) responsible for a reduced mitochondrial activity and inhibition of mitochondrial reactive oxygen species production (109). Interestingly, β3-ARs are highly expressed in cancer stem cells, and our studies in melanoma have clearly demonstrated that β3-ARs are involved in the enhancement stem-like traits, such as CD133, and CD20 expression and P1 melanosphere formation (98).
More recently, β3-ARs have been demonstrated to be related with the maintenance of an undifferentiated state also in neuroblastoma cells (115). These data are in line with the demonstration that β3-ARs are precociously expressed in the first phases of embryogenesis (84). We hypothesize that during the first phases of embryogenesis, the strong hypoxia induces a precocious expression of β3-ARs that maintains embryo in an undifferentiated state. As pregnancy evolves, the placentation induces a progressive increase in oxygen levels, and this represents the signal for a reduction in the expression of β3-ARs, and therefore, the induction of differentiation. Therefore, β3-ARs appear again to play a similar role both in cancer and embryo. Finally, this study provides the first data demonstrating how β3-AR blockage can modulate distinct immune cell populations involved in the immune tolerance process during pregnancy. These data are consistent with those recently demonstrated around and within the tumor (105). If these data will be confirmed and supported by further experiments (for example in the early stages of pregnancy), it will be possible to imagine a decisive role of β3-AR in promoting fetal and tumor immune tolerance.
Limitations and Perspectives
There are several limitations in this study.
The exploratory nature of this research, aimed at evaluating a possible role of the β3-ARs in the modulation of the cells involved in fetal immunotolerance, is confirmed by the limited number of animals involved. It is therefore evident that a much larger number of experiments are required to confirm the reproducibility of our data.
Inbred mice were chosen because of the high reproducibility of results that allowed reducing sample size, and therefore the number of animals used (116). The choice of this animal model deserves criticism. In fact, this study was performed on a simplified pregnancy model, between syngeneic animals with restricted polygenic diversity. However, in C57BL/6J pregnant mice, immune tolerance is preserved and therefore this mouse strain can represent a valid model for exploratory studies (117). Rather, the demonstration that the blockade of β3-ARs induces a sensitive modulation of the cells involved in fetal immune tolerance in this “low immunologic impact” model could suggest an even more relevant impact in allogeneic pregnancies. Also in this case, the exploratory role of this study is evident, and it therefore becomes necessary to repeat this study in allogeneic pregnancies.
In this study, we decided to treat mice with the β3-AR antagonist during the second week of gestation. Also, this choice may appear legitimately questionable and criticizable, especially if our hypothesis envisages hypoxia as a trigger for modulating the immune phenotype. In fact, if the oxygenation of the murine placenta behaved like the human placenta, with a positive correlation between placental oxygenation and gestational age, our hypothesis should be tested at an early stage of pregnancy (108). However, the oxygenation of the murine placenta does not undergo particular variations in the period between 10 and 18 days of pregnancy (118). In contrast, the lowest oxygen values appear to be observed around the eighteenth day of pregnancy (119). These observations therefore legitimize our choice of intervention timing.
Finally, the adoption of this model did not make it possible to evaluate whether β3-AR blockade at an early stage of pregnancy could induce an increased abortion rate, essential information to evaluate the relevance of this receptor for tolerance induction in vivo and to evaluate a possible role in the implantation phase.
The significant limitations of this study require further investigation with a larger number of experiments.
Conclusion
In conclusion, this study presents a new hypothesis and a new interpretation on the development of fetal and tumor immune tolerance. Cancer appears to promote immune tolerance by using the same molecular strategy (mainly β3-AR-mediated) adopted by the embryo and fetus. In this light, TME might act like placental tissue, and cancer might be a disease that exploits the same strategies that allow the embryo to grow. Furthermore, this study indicates that the TME reactivates fetal competences, including immunosuppression, predominantly through the activation of β3-ARs.
Although clinical benefits are currently expected by the addition of available non-selective β-blockers, in the near future β3-AR blockade could represent a more effective strategy to overcome immunoediting.
Data Availability Statement
The datasets generated for this study are available on request to the corresponding author.
Ethics Statement
The animal study was reviewed and approved by Research permit #194/2015-PR approved by the Italian Ministry of Health.
Author Contributions
LF and MC developed the concept and experiments and wrote the manuscript. AD, AS, DB, VD, SC, AP, and PN performed and analyzed animal model and functional assays. CF revised the experiments and the manuscript.
Funding
The insurance for this clinical trial was financed by A. Meyer Hospital.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
We are most grateful to the Meyer’s Hospital Foundation for their support of our research activity.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.02098/full#supplementary-material
FIGURE S1 | Gating strategy of FACS analysis. Representative gating strategy on whole blood, placenta and decidua for NK, MDSC, Treg, and CD8 analysis.
Abbreviations
β-ARs, β-adrenergic receptors; APC, antigen-presenting cells; cNK, conventional natural killer; COX-2, cyclooxygenase-2; CTLA-4, cytotoxic T-lymphocyte antigen-4; dNK, decidual NK; FasL, Fas ligand; HLAs, human leukocyte antigens; IDO, indoleamine-2,3-dioxygenase; MDSC, myeloid derived suppressor cells; NK, natural killer; NKG2DL, NKG2D ligand; NFkB, nuclear factor-k B; PD-L1, programmed cell death-1 (PD-1)/PD-ligand 1; Treg, regulatory T cells; TGF-β, transforming growth factor-β; TME, tumor microenvironment.
References
1. Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat Med. (2013) 19:548–56. doi: 10.1038/nm.3160
2. Schumacher A, Sharkey DJ, Robertson SA, Zenclussen AC. Immune cells at the fetomaternal interface: how the microenvironment modulates immune cells to foster fetal development. J Immunol. (2018) 201:325–34. doi: 10.4049/jimmunol.1800058
3. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. (2007) 179:977–83. doi: 10.4049/jimmunol.179.2.977
4. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol. (2014) 96:1109–18. doi: 10.1189/jlb.3A0414-210R
5. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. (2009) 85:996–1004. doi: 10.1189/jlb.0708446
6. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. (2009) 182:240–9. doi: 10.4049/jimmunol.182.1.240
7. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. (2008) 66:1–9. doi: 10.1016/j.critrevonc.2007.07.004
8. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. (2007) 67:11438–46. doi: 10.1158/0008-5472.CAN-07-1882
9. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. (2003) 100:2645–50. doi: 10.1073/pnas.0437939100
10. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. (2008) 13:23–35. doi: 10.1016/j.ccr.2007.12.004
11. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. (2007) 67:10019–26. doi: 10.1158/0008-5472.CAN-07-2354
12. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. (2006) 176:284–90. doi: 10.4049/jimmunol.176.1.284
13. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. (2008) 118:3367–77. doi: 10.1172/JCI35213
14. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. (2004) 5:266–71. doi: 10.1038/ni1037
15. Zenclussen AC. Regulatory T cells in pregnancy. Springer Semin Immunopathol. (2006) 28:31–9. doi: 10.1007/s00281-006-0023-6
16. Chaouat G, Lédée-Bataille N, Zourbas S, Ostojic S, Dubanched S, Martal J, et al. Cytokines, implantation and early abortion: re-examining the Th1/Th2 paradigm leads to question the single pathway, single therapy concept. Am J Reprod Immunol. (2003) 50:177–86. doi: 10.1034/j.1600-0897.2003.00080.x
17. Waldmann H, Graca L, Cobbold S, Adams E, Tone M, Tone Y. Regualtory T cells and organ transplantation. Semin Immunol. (2004) 16:119–26. doi: 10.1016/j.smim.2003.12.007
18. Choi BM, Pae HO, Jeong YR, Kim YM, Chung HT. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun. (2005) 327:1066–71. doi: 10.1016/j.bbrc.2004.12.106
19. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod. (2004) 10:347–53. doi: 10.1093/molehr/gah044
20. Tilburgs T, Roelen DL, van der Mast BJ, van Schip JJ, Kleijburg C, de Groot-Swings GM, et al. Differential distribution of CD4(+) CD25(bright) and CD8(+) CD28(-) T-cells in decidua and maternal blood during human pregnancy. Placenta. (2006) 27(Suppl A):S47–53. doi: 10.1016/j.placenta.2005.11.008
21. Jin LP, Fan DX, Li DJ. Regulation of costimulatory signal in maternal-fetal immune tolerance. Am J Reprod Immunol. (2011) 66:76–83. doi: 10.1111/j.1600-0897.2010.00982.x
22. Nagamatsu T, Schust DJ. The immunomodulatory roles of macrophages at the maternal-fetal interface. Reprod Sci. (2010) 17:209–18. doi: 10.1177/1933719109349962
23. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, et al. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod. (2005) 11:865–70. doi: 10.1093/molehr/gah246
24. Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature. (2012) 490:102–6. doi: 10.1038/nature11462
25. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science. (2008) 322:1562–5. doi: 10.1126/science.1164511
26. Darrasse-Jèze G, Marodon G, Salomon BL, Catala M, Klatzmann D. Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood. (2005) 105:4715–21. doi: 10.1182/blood-2004-10-4051
27. Michaëlsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses in the developing human fetus. J Immunol. (2006) 176:5741–8. doi: 10.4049/jimmunol.176.10.5741
28. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. (1998) 10:1969–80. doi: 10.1093/intimm/10.12.1969
29. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. (2007) 450:566–9. doi: 10.1038/nature06306
30. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. (2007) 27:635–46. doi: 10.1016/j.immuni.2007.08.014
31. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. (2004) 21:503–13. doi: 10.1016/j.immuni.2004.08.010
32. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. (2004) 4:762–74. doi: 10.1038/nri1457
33. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. (2003) 9:1269–74. doi: 10.1038/nm934
34. Jabrane-Ferrat N, Siewiera J. The up side of decidual natural killer cells: new developments in immunology of pregnancy. Immunology. (2014) 141:490–7. doi: 10.1111/imm.12218
35. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. (2016) 16:112–23. doi: 10.1038/nri.2015.9
36. Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. (2016) 16:310–20. doi: 10.1038/nri.2016.34
37. Jabrane-Ferrat N. Features of human decidual NK Cells in healthy pregnancy and during viral infection. Front Immunol. (2019) 10:1397. doi: 10.3389/fimmu.2019.01397
38. Chao KH, Wu MY, Chen CD, Yang JH, Yang YS, Ho HN. The expression of killer cell inhibitory receptors on natural killer cells and activation status of CD4+ and CD8+ T cells in the decidua of normal and abnormal early pregnancies. Hum Immunol. (1999) 60:791–7. doi: 10.1016/s0198-8859(99)00049-x
39. King A, Allan DS, Bowen M, Powis SJ, Joseph S, Verma S, et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol. (2000) 30:1623–31. doi: 10.1002/1521-4141(200006)30:63.0.CO;2-M
40. Erkers T, Stikvoort A, Uhlin M. Lymphocytes in placental tissues: immune regulation and translational possibilities for immunotherapy. Stem Cells Int. (2017) 2017:5738371. doi: 10.1155/2017/5738371
41. Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D, et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci USA. (2010) 107:11918–23. doi: 10.1073/pnas.1001749107
42. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. (1997) 79:2320–8. doi: 10.1002/(sici)1097-0142(19970615)79:123.0.co;2-p
43. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. (2000) 88:577–83.
44. Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. (2002) 35:23–8. doi: 10.1016/s0169-5002(01)00292-6
45. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. (2003) 24:603–9. doi: 10.1016/j.it.2003.09.007
46. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer. (2008) 59:32–40. doi: 10.1016/j.lungcan.2007.07.022
47. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. (2012) 18:1201–6. doi: 10.1158/1078-0432.CCR-11-0641
48. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. (2006) 12:369–75. doi: 10.1158/1078-0432.CCR-05-1698
49. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. (2013) 123:874–86. doi: 10.1172/JCI63324
50. Lin Q, Wang F, Yang R, Zheng X, Gao H, Zhang P. Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One. (2013) 8:e61435. doi: 10.1371/journal.pone.0061435
51. Huang Q, Tan Q, Mao K, Yang G, Ma G, Luo P, et al. The role of adrenergic receptors in lung cancer. Am J Cancer Res. (2018) 8:2227–37.
52. Hasegawa H, Saiki I. Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res. (2002) 93:729–35. doi: 10.1111/j.1349-7006.2002.tb01313.x
53. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, et al. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. (2007) 282:29919–26. doi: 10.1074/jbc.M611539200
54. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. (2009) 23:267–75. doi: 10.1016/j.bbi.2008.10.005
55. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. (2010) 285:35462–70. doi: 10.1074/jbc.M110.109579
56. Bernabé DG, Tamae AC, Biasoli ÉR, Oliveira SH. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav Immun. (2011) 25:574–83. doi: 10.1016/j.bbi.2010.12.012
57. Valles SL, Benlloch M, Rodriguez ML, Mena S, Pellicer JA, Asensi M, et al. Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism. J Transl Med. (2013) 11:72. doi: 10.1186/1479-5876-11-72
58. Dokur M, Boyadjieva N, Sarkar DK. Catecholaminergic control of NK cell cytolytic activity regulatory factors in the spleen. J Neuroimmunol. (2004) 151:148–57. doi: 10.1016/j.jneuroim.2004.03.003
59. Shimizu N, Kaizuka Y, Hori T, Nakane H. Immobilization increases norepinephrine release and reduces NK cytotoxicity in spleen of conscious rat. Am J Physiol. (1996) 271:R537–44. doi: 10.1152/ajpregu.1996.271.3.R537
60. Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol. (1998) 160:3251–8.
61. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer. (1999) 80:880–8. doi: 10.1002/(sici)1097-0215(19990315)80:63.0.co;2-y
62. Tønnesen E, Christensen NJ, Brinkløv MM. Natural killer cell activity during cortisol and adrenaline infusion in healthy volunteers. Eur J Clin Invest. (1987) 17:497–503. doi: 10.1111/j.1365-2362.1987.tb01148.x
63. Tønnesen E, Brinkløv MM, Christensen NJ, Olesen AS, Madsen T. Natural killer cell activity and lymphocyte function during and after coronary artery bypass grafting in relation to the endocrine stress response. Anesthesiology. (1987) 67:526–33. doi: 10.1097/00000542-198710000-00014
64. Pedersen BK, Tvede N, Hansen FR, Andersen V, Bendix T, Bendixen G, et al. Modulation of natural killer cell activity in peripheral blood by physical exercise. Scand J Immunol. (1988) 27:673–8. doi: 10.1111/j.1365-3083.1988.tb02400.x
65. Klokker M, Secher NH, Madsen P, Pedersen M, Pedersen BK. Adrenergic beta 1- and beta 1 + 2-receptor blockade suppress the natural killer cell response to head-up tilt in humans. J Appl Physiol. (1997) 83:1492–8. doi: 10.1152/jappl.1997.83.5.1492
66. Palmø J, Asp S, Daugaard JR, Richter EA, Klokker M, Pedersen BK. Effect of eccentric exercise on natural killer cell activity. J Appl Physiol. (1995) 78:1442–6. doi: 10.1152/jappl.1995.78.4.1442
67. Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, et al. Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol. (2013) 43:1001–12. doi: 10.1002/eji.201243005
68. Schmidt D, Peterlik D, Reber SO, Lechner A, Männel DN. Induction of suppressor cells and increased tumor growth following chronic psychosocial stress in male mice. PLoS One. (2016) 11:e0159059. doi: 10.1371/journal.pone.0159059
69. Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol. (2011) 270:80–7. doi: 10.1016/j.cellimm.2011.04.003
70. Liu Y, Wei J, Guo G, Zhou J. Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species. Immunopharmacol Immunotoxicol. (2015) 37:359–65. doi: 10.3109/08923973.2015.1059442
71. Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. (2017) 7:e1405205. doi: 10.1080/2162402X.2017.1405205
72. Phillippe M. Fetal catecholamines. Am J Obstet Gynecol. (1983) 146:840–55. doi: 10.1016/0002-9378(83)91088-8
73. Portbury AL, Chandra R, Groelle M, McMilli MK, Elias A, Herlong JR, et al. Catecholamines act via a beta-adrenergic receptor to maintain fetal heart rate and survival. Am J Physiol Heart Circ Physiol. (2003) 284:H2069–77. doi: 10.1152/ajpheart.00588.2002
74. Thomas SA, Matsumoto AM, Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature. (1995) 374:643–6. doi: 10.1038/374643a0
75. Zhou QY, Quaife CJ, Palmiter RD. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature. (1995) 374:640–3. doi: 10.1038/374640a0
76. Kudo T. Role of fetal catecholamines before and during birth. Nihon Sanka Fujinka Gakkai Zasshi. (1989) 41:1027–32.
77. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. (2011) 29:2635–44. doi: 10.1200/JCO.2010.33.5422
78. Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer. (2015) 15:426–31. doi: 10.1016/j.clbc.2015.07.001
79. Yazawa T, Kaira K, Shimizu K, Shimizu A, Mori K, Nagashima T, et al. Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res. (2016) 8:5059–70.
80. De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol. (2018) 4:e172908. doi: 10.1001/jamaoncol.2017.2908
81. Adeoya-Osiguwa SA, Gibbons R, Fraser LR. Identification of functional alpha2- and beta-adrenergic receptors in mammalian spermatozoa. Hum Reprod. (2006) 21:1555–63. doi: 10.1093/humrep/del016
82. Cikos S, Veselá J, Il’ková G, Rehák P, Czikková S, Koppel J. Expression of beta adrenergic receptors in mouse oocytes and preimplantation embryos. Mol Reprod Dev. (2005) 71:145–53. doi: 10.1002/mrd.20256
83. Èikoš Š, Czikková S, Chrenek P, Makarevich AV, Burkuš J, Janštová Ž, et al. Expression of adrenergic receptors in bovine and rabbit oocytes and preimplantation embryos. Reprod Domest Anim. (2014) 49:92–100. doi: 10.1111/rda.12233
84. Fujinaga M, Scott JC. Gene expression of catecholamine synthesizing enzymes and beta adrenoceptor subtypes during rat embryogenesis. Neurosci Lett. (1997) 231:108–12. doi: 10.1016/s0304-3940(97)00511-9
85. Resch BE, Ducza E, Gáspár R, Falkay G. Role of adrenergic receptor subtypes in the control of human placental blood vessels. Mol Reprod Dev. (2003) 66:166–71. doi: 10.1002/mrd.10337
86. Hynes PG, Friel AM, Smith TJ, Morrison JJ. Beta-adrenoceptor subtype expression in human placenta and umbilical arteries in normal and preeclamptic pregnancies. Hypertens Pregnancy. (2008) 27:169–81. doi: 10.1080/10641950701826554
87. Rouget C, Bardou M, Breuiller-Fouché M, Loustalot C, Qi H, Naline E, et al. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab. (2005) 90:1644–50. doi: 10.1210/jc.2004-0233
88. Bardou M, Rouget C, Breuiller-Fouché M, Loustalot C, Naline E, Sagot P, et al. Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs? BMC Pregnancy Childbirth. (2007) 7(Suppl. 1):S14. doi: 10.1186/1471-2393-7-S1-S14
89. Perrone MG, Notarnicola M, Caruso MG, Tutino V, Scilimati A. Upregulation of beta3-adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology. (2008) 75:224–9. doi: 10.1159/000163851
90. Lamkin DM, Sloan EK, Patel AJ, Chiang BS, Pimentel MA, Ma JC, et al. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav Immun. (2012) 26:635–41. doi: 10.1016/j.bbi.2012.01.013
91. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. β-Adrenergic receptor expression in vascular tumors. Mod Pathol. (2012) 25:1446–51. doi: 10.1038/modpathol.2012.108
92. Babol K, Przybylowska K, Lukaszek M, Pertynski T, Blasiak J. An association between the Trp64Arg polymorphism in the beta3-adrenergic receptor gene and endometrial cancer and obesity. J Exp Clin Cancer Res. (2004) 23:669–74.
93. Huang XE, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwata H, et al. Possible association of beta2- and beta3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer. Breast Cancer Res. (2001) 3:264–9. doi: 10.1186/bcr304
94. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. (2013) 341:1236361. doi: 10.1126/science.1236361
95. Dal Monte M, Casini G, Filippi L, Nicchia GP, Svelto M, Bagnoli P. Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization. J Mol Med (Berl). (2013) 91:1407–19. doi: 10.1007/s00109-013-1073-6
96. Sereni F, Dal Monte M, Filippi L, Bagnoli P. Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol. (2015) 388:1317–31. doi: 10.1007/s00210-015-1165-7
97. Dal Monte M, Fornaciari I, Nicchia GP, Svelto M, Casini G, Bagnoli P. β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. Naunyn Schmiedebergs Arch Pharmacol. (2014) 387:533–43. doi: 10.1007/s00210-014-0969-1
98. Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S, et al. Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression. Oncotarget. (2015) 6:4615–32. doi: 10.18632/oncotarget.2652
99. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional beta (3)-adrenergic receptor in the failing canine myocardium. Circ Res. (2001) 89:599–606. doi: 10.1161/hh1901.098042
100. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta (3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. (2001) 103:1649–55. doi: 10.1161/01.cir.103.12.1649
101. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. (2004) 110:948–54. doi: 10.1161/01.CIR.0000139331.85766.AF
102. Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. (2011) 52:155–70. doi: 10.1167/iovs.10-5536
103. Chen J, Joyal JS, Hatton CJ, Juan AM, Pei DT, Hurst CG, et al. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. (2012) 53:2968–77. doi: 10.1167/iovs.12-9691
104. Dal Monte M, Filippi L, Bagnoli P. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol. (2013) 386:269–78. doi: 10.1007/s00210-012-0828-x
105. Calvani M, Bruno G, Dal Monte M, Nassini R, Fontani F, Casini A, et al. β(3)-Adrenoceptor as a potential immuno-suppressor agent in melanoma. Br J Pharmacol. (2019) 176:2509–24. doi: 10.1111/bph.14660
106. Silván U, Díez-Torre A, Arluzea J, Andrade R, Silió M, Aréchaga J. Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology. Differentiation. (2009) 78:159–68. doi: 10.1016/j.diff.2009.06.002
107. Manzo G. Similarities between embryo development and cancer process suggest new strategies for research and therapy of tumors: a new point of view. Front Cell Dev Biol. (2019) 7:20. doi: 10.3389/fcell.2019.00020
108. Jauniaux E, Watson A, Burton G. Evaluation of respiratory gases and acid-base gradients in human fetal fluids and uteroplacental tissue between 7 and 16 weeks’ gestation. Am J Obstet Gynecol. (2001) 184:998–1003. doi: 10.1067/mob.2001.111935
109. Calvani M, Cavallini L, Tondo A, Spinelli V, Ricci L, Pasha A, et al. β3-adrenoreceptors control mitochondrial dormancy in melanoma and embryonic stem cells. Oxid Med Cell Longev. (2018) 2018:6816508. doi: 10.1155/2018/6816508
110. Redel BK, Brown AN, Spate LD, Whitworth KM, Green JA, Prather RS. Glycolysis in preimplantation development is partially controlled by the Warburg Effect. Mol Reprod Dev. (2012) 79:262–71. doi: 10.1002/mrd.22017
111. Zuo RJ, Gu XW, Qi QR, Wang TS, Zhao XY, Liu JL, et al. Warburg-like glycolysis and lactate shuttle in mouse decidua during early pregnancy. J Biol Chem. (2015) 290:21280–91. doi: 10.1074/jbc.M115.656629
112. Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. (2019) 7:4. doi: 10.3389/fcell.2019.00004
113. Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. (2019) 95:912–9. doi: 10.1080/09553002.2019.1589653
114. Smith DG, Sturmey RG. Parallels between embryo and cancer cell metabolism. Biochem Soc Trans. (2013) 41:664–9. doi: 10.1042/BST20120352
115. Bruno G, Cencetti F, Pini A, Tondo A, Cuzzubbo D, Fontani F, et al. β3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P(2) modulation. Oncogene. (2020) 39:368–84. doi: 10.1038/s41388-019-0993-1
116. Festing MF. On determining sample size in experiments involving laboratory animals. Lab Anim (2018) 52:341–50. doi: 10.1177/0023677217738268
117. Li Y, Lopez GE, Vazquez J, Sun Y, Chavarria M, Lindner PN, et al. Decidual-placental immune landscape during syngeneic murine pregnancy. Front Immunol. (2018) 9:2087. doi: 10.3389/fimmu.2018.02087
118. Basak K, Luís Deán-Ben X, Gottschalk S, Reiss M, Razansky D. Non-invasive determination of murine placental and foetal functional parameters with multispectral optoacoustic tomography. Light Sci Appl. (2019) 8:71. doi: 10.1038/s41377-019-0181-7
Keywords: beta-blockers, beta-adrenergic, fetal immune tolerance, cancer immune-tolerance, embryo implantation
Citation: Calvani M, Dabraio A, Subbiani A, Buonvicino D, De Gregorio V, Ciullini Mannurita S, Pini A, Nardini P, Favre C and Filippi L (2020) β3-Adrenoceptors as Putative Regulator of Immune Tolerance in Cancer and Pregnancy. Front. Immunol. 11:2098. doi: 10.3389/fimmu.2020.02098
Received: 15 March 2020; Accepted: 03 August 2020;
Published: 02 September 2020.
Edited by:
Julia Szekeres-Bartho, Medical School, University of Pécs, HungaryReviewed by:
Anne Schumacher, Otto von Guericke University Magdeburg, GermanyNandor Gabor Than, Research Centre for Natural Sciences, Hungarian Academy of Sciences (MTA), Hungary
Copyright © 2020 Calvani, Dabraio, Subbiani, Buonvicino, De Gregorio, Ciullini Mannurita, Pini, Nardini, Favre and Filippi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luca Filippi, l.filippi@meyer.it; luca.filippi@meyer.it